Merck (MRK) Income from Discontinued Operations (2020 - 2021)
Merck's (MRK) quarterly Income from Discontinued Operations came in at -$62.0 million in Q4 2021, down 111.85% year-over-year from $523.0 million in Q4 2020, and down 118.67% quarter-over-quarter from $332.0 million in Q2 2021.
Analysis
Merck (MRK) Income from Discontinued Operations (2020 - 2021) Analysis & Trends
Merck (MRK) has reported Income from Discontinued Operations for 2 consecutive years, with -$62.0 million the latest figure, recorded in Q4 2021.
- On a quarterly basis, Income from Discontinued Operations fell 111.85% year-over-year to -$62.0 million in Q4 2021; TTM through Sep 2022 was -$62.0 million, a 104.8% decrease from a year earlier, with the FY2021 full-year figure at $707.0 million, down 72.37% from the prior year.
- Income from Discontinued Operations was -$62.0 million for Q4 2021 at Merck, down from $332.0 million in the prior quarter.
- Over five years, Income from Discontinued Operations peaked at $665.0 million in Q2 2020 and troughed at -$62.0 million in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 8.00 Mn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | - |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | -62.00 Mn |
| Jun 30, 2021 | 332.00 Mn |
| Mar 31, 2021 | 437.00 Mn |
| Dec 31, 2020 | 523.00 Mn |
| Sep 30, 2020 | 619.00 Mn |
| Jun 30, 2020 | 665.00 Mn |